Background: Studies demonstrated that supplementation of adult men with selenium-enriched
Introduction
Prostate Cancer (PCa) presents a major clinical and public health challenge in the USA. It is the second leading cause of cancer-related deaths in men and second only to lung cancer (1) .
Men have a 1 in 6 lifetime probability of being diagnosed with PCa. PCa has surpassed heart disease as the top killer of men over the age of 85 years in the USA; 192,000 men were diagnosed with PCa and 27,360 died from this disease in 2009 (1) . The incidence and mortality of PCa vary significantly across ethnic groups with African American (AA) men having the highest rates in the world (2) . Though the etiology of PCa remains poorly understood, epidemiological studies have revealed a number of risk factors including diet, lifestyle and environmental factors that significantly contribute to the development of this disease (3, 4) .
Diet derived-agents including selenium have been shown to have chemopreventive potential against PCa (5) . Based on the epidemiologic evidence as well as preclinical studies and some clinical intervention trials, selenium has emerged as a strong contender in the arena of cancer chemoprevention (6) . In the Nutritional Prevention Trial, SY supplementation was associated with a reduction in PCa development (7, 8) . The form of selenium has been shown in both clinical and preclinical studies to be an important determinant in chemopreventive efficacy. In the recently conducted Selenium and Vitamin E Cancer Prevention Trial (SELECT), selenomethionine (SM) was tested for its activity against PCa (9) . Unfortunately, this trial was stopped prematurely because, in part, of the lack of a protective effect of SM against PCa and a non-significant increase in type II diabetes. SM, when used in animal models, demonstrated either little or no activity in the chemoprevention of PCa (6, 10, 11) . In addition to SM, seleniumenriched yeast contains other forms of selenium that appear to be more effective than SM.
Clearly, there is an urgent need to develop more effective selenium-based agents and appropriate biomarkers that can be altered by selenium intervention in future clinical studies (12) .
Author manuscripts have been peer reviewed and accepted for publication but Candidate spot picking and processing. To obtain enough protein/spot that will allow in-gel digestion and peptide sequencing by LC/MS/MS we ran a semi-preparative 2D-PAGE ("picking gel") using a total of 300 μg of protein without Cy Dye labeling. After 1 st and 2 nd dimension electrophoresis using the parameters described above, the gel was stained in the dark for 1 hr with SyproRuby (Invitrogen, Carlsbad, CA) with shaking. The stained gel was rinsed with distilled water and scanned with the Typhoon Trio using the excitation (532 nm) and emission and chromatographed with the Surveyor HPLC system. The peptides were separated using two buffer systems: Buffer A (0.1% formic acid in water) and Buffer B (0.1% formic acid in acetonitrile) at a flow rate of 4 μl /min. The gradient used was 2-50% Buffer A in 45 min. As peptides eluted from the column, they were subjected to ESI-Ion-trap ms as follows: i) single full ms scan to determine the masses of analytes and ii) tandem ms of the three biggest peaks from the preceding full scan to obtain the sequence information. This process was repeated every 15 sec during the gradient. All the ms/ms spectra obtained were searched against the NCBI nonredundant protein sequence database using the SEQUEST computer algorithm to establish the protein identity (26) .
Gene ontology classification. The 11 proteins of interest were assigned molecular functions, biological processes and cellular components according to the unified Gene Ontology (GO)
Consortium classification (27) , to determine their validated or putative role in several cancers including prostate cancer. The GO categories assigned to the proteins of interest were determined by using the gene ID of each protein to search the GO database to obtain the function, process and component assigned to each protein (28) . Figure 1A shows the possible isoforms (indicated by arrows) of AAT being reduced in sera from SY supplemented individuals after 9-months of treatment; however, CLU was up regulated after SY-supplementation.
Two
AAT was further examined in three representative serum samples from placebo and SY supplemented healthy men. Our rationale for further analysis of AAT was based on literature data demonstrating that levels of AAT vary with race and are correlated with PSA levels (29) .
Influence of SY supplementation on AAT levels. Serum samples from placebo and SYsupplemented healthy men were examined for AAT levels at baseline, and at 3 and 9 months after supplementation in addition to analyzing samples at 12 months from the start of the study.
The AAT ELISA showed that there was a slight (nonsignificant) elevation at 3 months for the placebo group but thereafter the AAT levels appear to decline at 9 and 12 months ( Figure 2 ).
The SY supplemented group, however, showed a significant decrease in the AAT levels at 9 months (p<0.05) when compared to the baseline levels ( Figure 2) . However, at 9 months the difference observed in mean AAT between placebo and supplemented groups was not significant. After a 3 month washout period (12 month time-point) AAT levels in the selenium supplemented group were comparable to baseline. Overall, AAT levels in supplemented individuals were inversely correlated with changes in selenium levels from baseline at 3, 9 and 12 months with r values ranging from -0.47 to -0.59 (p<0.05).
Further evaluation of AAT levels indicated differences between Caucasians and AA.
AAT levels for AA were consistently higher than Caucasians at any given time point during the study. Following supplementation, AAT levels in Caucasians were significantly lower (p<0.05)
than those compared to AA at 3 months ( Figure 3A) . Moreover, in AA the AAT levels were lowered significantly by 3 and 9 months of SY supplementation compared to baseline (p<0.05), while in Caucasians the levels of AAT were significantly (p<0.05) reduced only after 9 months 
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Copyright © 2010 American Association for Cancer Research where they remained lower even after 12 months (p<0.05) ( Figure 3A) . Interestingly, since SYsupplementation was terminated after 9 months, the levels of AAT in AA started to recover at 12 month interval while in Caucasians these levels remained significantly lower (p<0.05) than those at baseline. SY appears to equally reduce PSA levels in both Caucasians and AA ( Figure 3B ).
Discussion
In the present study, proteomic analysis of serum from participants of our previous trial (24) revealed 11 proteins that were significantly altered after 9-months of SY supplementation, all of which are redox sensitive or involved in the regulation of redox status. The GO classification of the selected proteins revealed that 7 out of the 11 play a role in cancer development including prostate cancer (Table 2 ). For example, Alpha-1B glycoprotein is over expressed in pancreatic cancer (30) , haptoglobin is differentially expressed in adenocarcinoma of the uterus (31) and transthyretin expression is reduced in lung cancer (32) and in cholangiocarcinoma (33) .
Additionally, Transferrin and Angiotensin precursor are implicated in lung cancer (34) and renal cell carcinoma (35) , respectively. Our hypothesis that selenium may inhibit oxidative stress and other markers of risk for PCa due to covalent interactions of selenium with thiol containing redox-sensitive proteins is supported in part by our previous study (36) . However, future studies are required to determine the basis for SY alteration of the redox-sensitive proteins identified in this study.
Of particular interest was our finding that AAT and CLU were among the proteins most affected by SY, as these have been previously linked to the development of PCa (37) (38) (39) . CLU, a glycoprotein, is believed to be involved in many diseases including cancer (reviewed in 37).
CLU gene is a regulator of apoptosis, cell-cell interactions, protein stability, cell signaling, proliferation, and transformation. In humans, the CLU gene is located on chromosome 8 in a region that is frequently deleted in prostate cancer (8p21-p12) (37 Our findings that AAT levels are significantly decreased by SY and are highly correlated with an increase in blood selenium levels are consistent with a possible reduction in PCa risk.
Elevations in serum levels of AAT, a marker of inflammation, in PCa patients are well documented. Serum levels of AAT are increased by inflammation as well as infection (42, 43) .
Blood levels of AAT are tightly regulated and increased in PCa patients. In fact, levels of various proteins including AAT correlated with disease severity and decreased in patients with favorable response to treatment (44, 45) . Similarly, a decrease in PSA levels is usually observed in PCa patients who respond to treatment, whereas increased levels are indicative of poor prognosis (46, 47) . It is thought that inflammation of the prostate or prostatitis may lead to PCa by mechanisms that remain to be fully elucidated. Furthermore, it was reported that men with PCa associated with metastasis had higher serum levels of AAT than those with less advanced disease (48) . In the current study, we showed that AAT levels for AA were higher than that for
Caucasians at any given time point during the trial. This result is consistent with the literature data demonstrating that AA have higher levels of AAT as well as PSA than Caucasians (29) . In addition, an age associated increase in AAT levels, especially in AA, was also reported (29) .
Re-analysis of our previous pilot selenium trial data (24) indicated that the increase in plasma selenium by SY supplementation was much lower in AA than in Caucasians (unpublished data*). These results are consistent with recent analysis of US population data from National Health and Nutrition Examination Survey (NHANESIII) (49) where selenium levels were about 6% lower in AA than in caucasians after adjustment for known predictors of serum selenium. In the present study we showed that SY supplementation resulted in significantly lower AAT levels in caucasians than those compared to AA at a 3-month time point. Our results also demonstrate that the levels of AAT in AA recovered at 12 month faster than those found in caucasians. Collectively, these results suggest that lower selenium levels in AA (49, unpublished data*) may, in part, contribute to their higher rate of cancer, particularly, PCa underscoring the need to tailor future clinical chemoprevention trials according to race.
Independent of the mechanism that can account for the alterations of levels of proteins identified in this study including AAT and CLU by SY, we propose that in addition to the standard PSA test, both proteins are potential candidate biomarkers that can be employed in pilot clinical trials using selenium.
At present, our knowledge on the mechanisms that may account for cancer prevention by various forms of selenium is based primarily on animal model studies and assays in cultured prostate cancer cells (6, 19, 50) . Unfortunately, how such knowledge can be applied to humans is unclear and this void presents a great challenge in the design of future clinical trials. At present a clinical study is currently being conducted in our laboratory aimed at comparing the effect of SM and SY under identical conditions, on protein profiles and on biomarkers of PCa 
